 | |
  | |
| Searching ... |
| 0 % | ||
Books by Erin Balogh
  | | Improving Diagnosis in Health Care(1st Edition) (Quality Chasm) by Institute Of Medicine, Erin P. Balogh, John R. Ball, Bryan T. Miller, Nasem Nasem, National Academies Press Paperback, 472 Pages, Published 2016 by National Academies Press ISBN-13: 978-0-309-37769-0, ISBN: 0-309-37769-2 "Getting the right diagnosis is a key aspect of health care - it provides an explanation of a patient's health problem and informs subsequent health care decisions. The diagnostic process is a complex, collaborative activity that involves clinical reasoning and information gathering to determine a patient's health problem. According to Improving Diagnosis in Health Care, diagnostic errors-inaccurate or delayed diagnoses-persist throughou ..." |
 | | Delivering High-Quality Cancer Care(1st Edition) Charting a New Course for a System in Crisis (Cancers and Children) by Institute Of Medicine, Sharyl J. Nass, Laura A. Levit, Erin P. Balogh, Patricia A. Ganz Paperback, 412 Pages, Published 2014 by National Academies Press ISBN-13: 978-0-309-28660-2, ISBN: 0-309-28660-3 "In the United States, approximately 14 million people have had cancer and more than 1.6 million new cases are diagnosed each year. However, more than a decade after the Institute of Medicine (IOM) first studied the quality of cancer care, the barriers to achieving excellent care for all cancer patients remain daunting. Care often is not patient-centered, many patients do not receive palliative care to manage their symptoms and side effe ..." |
 | | Cancer Care in Low-Resource Areas Cancer Prevention and Early Detection: Workshop Summary by Institute Of Medicine, Sharyl J. Nass, Margie Patlak, Erin Balogh Paperback, 126 Pages, Published 2016 by National Academies Press ISBN-13: 978-0-309-39101-6, ISBN: 0-309-39101-6 "Though cancer was once considered to be a problem primarily in wealthy nations, low- and middle-income countries now bear a majority share of the global cancer burden, and cancer often surpasses the burden of infectious diseases in these countries. Effective low-cost cancer control options are available for some malignancies, with the World Health Organization estimating that these interventions could facilitate the prevention of approx ..." |
 | | Perspectives on Biomarker and Surrogate Endpoint Evaluation(1st Edition) Discussion Forum Summary by Institute Of Medicine, Alison Mack, Erin Balogh, Christine M. Micheel, Nutrition Board Paperback, 140 Pages, Published 2011 by National Academies Press ISBN-13: 978-0-309-16324-8, ISBN: 0-309-16324-2 "In 2010 the Institute of Medicine (IOM) recommended a framework for the evaluation of biomarkers in the chronic disease setting. Published in the book Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease, the framework is intended to bring consistency and transparency to the previously disparate process of biomarker evaluation. Following the book's release, the IOM convened a 2-day discussion forum in Washington, DC, in ..." |
 | | Patient-Centered Cancer Treatment Planning Improving the Quality of Oncology Care: Workshop Summary by Margie Patlak, Erin Balogh, Sharyl Nass Published 2011 ISBN-13: 978-1-283-25351-2, ISBN: 1-283-25351-8 |
 | | Health Literacy and Communication Strategies in Oncology Proceedings of a Workshop by Sharyl Nass, Joe Alper, Erin Balogh, Emily Zavon Paperback, 78 Pages, Published 2020 by National Academies Press ISBN-13: 978-0-309-67105-7, ISBN: 0-309-67105-1 "Health literacy is a critical skill for engaging in healthy behaviors to reduce disease risk and improve health outcomes across the continuum of cancer care. However, estimates suggest that more than one-third of the U.S. adult population has low health literacy, and nearly half of all patients with cancer have difficulty understanding information about their disease or treatment. Low health literacy among patients with cancer is associ ..." |
 | | Developing and Sustaining an Effective and Resilient Oncology Careforce(1st Edition) Proceedings of a Workshop by Sharyl J. Nass, Margie Patlak, Emily Zevon, Erin Balogh Paperback, 82 Pages, Published 2019 by National Academies Press ISBN-13: 978-0-309-49604-9, ISBN: 0-309-49604-7 "The oncology careforce faces challenges as population growth in the U.S. contributes to increases in the number of patients diagnosed with cancer. Significant advances in cancer research, screening and diagnostic practices, and treatment have led to the age-adjusted declining mortality rate from cancer. However, as the field continues to develop and advance, cancer care has become more complex than ever before. There is a growing concer ..." |
 | | Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors Proceedings of a Workshop by Sharyl J. Nass, Erin Balogh Paperback, 88 Pages, Published 2019 by National Academies Press ISBN-13: 978-0-309-49086-3, ISBN: 0-309-49086-3 "In recent years, significant progress has been made in the clinical development and use of various types of cancer immunotherapy, all of which rely on the immune system to fight cancer. The majority of new cancer drug applications submitted to the Food and Drug Administration (FDA) are for immunotherapies or combinations involving immunotherapies. One type of immunotherapy is an immune checkpoint inhibitor. Cells in the human body have ..." |
 | | Improving Cancer Diagnosis and Care Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: Proceedings of a Workshop by Sharyl J. Nass, Margie Patlak, Erin Balogh Paperback, 92 Pages, Published 2019 by National Academies Press ISBN-13: 978-0-309-47828-1, ISBN: 0-309-47828-6 "Rapid advances in cancer research, the development of new and more sophisticated approaches to diagnostic testing, and the growth in targeted cancer therapies are transforming the landscape of cancer diagnosis and care. These innovations have contributed to improved outcomes for patients with cancer, but they have also increased the complexity involved in diagnosis and subsequent care decisions. To examine opportunities to improve cance ..." |
 | | The Drug Development Paradigm in Oncology Proceedings of a Workshop (Clinical Trial Data Sharing) by Sharyl J. Nass, Margie Patlak, Erin Balogh, Amanda Wagner Gee Paperback, 144 Pages, Published 2018 by National Academies Press ISBN-13: 978-0-309-45794-1, ISBN: 0-309-45794-7 "Advances in cancer research have led to an improved understanding of the molecular mechanisms underpinning the development of cancer and how the immune system responds to cancer. This influx of research has led to an increasing number and variety of therapies in the drug development pipeline, including targeted therapies and associated biomarker tests that can select which patients are most likely to respond, and immunotherapies that ha ..." |
 | | Implementation of Lung Cancer Screening Proceedings of a Workshop by Sharyl J. Nass, Margie Patlak, Erin Balogh Paperback, 126 Pages, Published 2017 by National Academies Press ISBN-13: 978-0-309-45132-1, ISBN: 0-309-45132-9 "The public health burden from lung cancer is substantial: it is the second most commonly diagnosed cancer and the leading cause of cancer-related deaths in the United States. Given the individual and population health burden of lung cancer, especially when it is diagnosed at later stages, there has been a push to develop and implement screening strategies for early detection. However, many factors need to be considered for broad impleme ..." |
 | | Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment(1st Edition) Proceedings of a Workshop by Sharyl J. Nass, Margie Patlak, Kimberly Maxfield, Erin Balogh Paperback, 134 Pages, Published 2016 by National Academies Press ISBN-13: 978-0-309-44232-9, ISBN: 0-309-44232-X "Immunotherapy is a form of cancer therapy that harnesses the bodya (TM)s immune system to destroy cancer cells. In recent years, immunotherapies have been developed for several cancers, including advanced melanoma, lung cancer, and kidney cancer. In some patients with metastatic cancers who have not responded well to other treatments, immunotherapy treatment has resulted in complete and durable responses. Given these promising findings, ..." |
 | | Reducing Tobacco-Related Cancer Incidence and Mortality(1st Edition) Workshop Summary by Institute Of Medicine, Erin Balogh, Margie Patlak, Sharyl J. Nass Paperback, 115 Pages, Published 2013 by National Academies Press ISBN-13: 978-0-309-26401-3, ISBN: 0-309-26401-4 "Tobacco use is the leading cause of preventable death in United States, causing more than 440,000 deaths annually and resulting in $193 billion in health-related economic losses each year--$96 billion in direct medical costs and $97 billion in lost productivity. Since the first U.S. Surgeon General's report on smoking in 1964, more than 29 Surgeon General's reports, drawing on data from thousands of studies, have documented the overwhel ..." |
 | | Delivering Affordable Cancer Care in the 21st Century(1st Edition) Workshop Summary by Institute Of Medicine, Erin Balogh, Margie Patlak, Sharyl J. Nass Paperback, 94 Pages, Published 2013 by National Academies Press ISBN-13: 978-0-309-26944-5, ISBN: 0-309-26944-X "Rising health care costs are a central fiscal challenge confronting the United States. National spending on health care currently accounts for 18 percent of gross domestic product (GDP), but is anticipated to increase to 25 percent of GDP by 2037. The Bipartisan Policy Center argues that "this rapid growth in health expenditures creates an unsustainable burden on America's economy, with far-reaching consequences". These consequences inc ..." |
 | | Facilitating Collaborations to Develop Combination Investigational Cancer Therapies(1st Edition) Workshop Summary by Institute Of Medicine, Erin Balogh, Margie Patlak, Sharyl J. Nass Paperback, 118 Pages, Published 2012 by National Academies Press ISBN-13: 978-0-309-22064-4, ISBN: 0-309-22064-5 "Advances in biomedical research have increased our understanding of the complex nature of disease and the interaction of multiple molecular pathways involved in cancer. Combining investigational products early in their development is thought to be a promising strategy for identifying effective therapies. The IOM's National Cancer Policy Forum held a workshop to discuss challenges and identify potential solutions to improve collaboration ..." |
 | | The National Cancer Policy Summit(1st Edition) Opportunities and Challenges in Cancer Research and Care: Workshop Summary by Institute Of Medicine, Margie Patlak, Erin Balogh, Sharyl J. Nass, Sharyl J. Naus Paperback, 60 Pages, Published 2011 by National Academies Press ISBN-13: 978-0-309-18739-8, ISBN: 0-309-18739-7 "Many ongoing changes are likely to have an impact on cancer research and care. For example, technological advances are rapidly changing the way cancer research is conducted, and the recently passed healthcare reform legislation has many implications for cancer care. Technological advances are altering the way cancer research is conducted and cancer care is delivered, and the recently passed healthcare reform legislation has many implica ..." |
 | | Patient-Centered Cancer Treatment Planning(1st Edition) Improving the Quality of Oncology Care: Workshop Summary by Institute Of Medicine, Margie Patlak, Erin Balogh, Sharyl J. Nass Paperback, 90 Pages, Published 2011 by National Academies Press ISBN-13: 978-0-309-21273-1, ISBN: 0-309-21273-1 "Each year approximately 1.5 million people are diagnosed with cancer in the United States, most of whom inevitably face difficult decisions concerning their course of care. Recognizing challenges associated with cancer treatment, the National Coalition for Cancer Survivorship (NCCS) and the National Cancer Policy Forum (NCPF) of the Institute of Medicine (IOM) hosted a public workshop in Washington, DC on February 28 and March 1, 2011, ..." |
 | | Extending the Spectrum of Precompetitive Collaboration in Oncology Research(1st Edition) Workshop Summary by Institute Of Medicine, Margie Patlak, Erin Balogh, Sharyl J. Nass Paperback, 112 Pages, Published 2010 by National Academies Press ISBN-13: 978-0-309-15654-7, ISBN: 0-309-15654-8 "Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no greater now than it was 50 years ago. Over the past decade, skyrocketing costs and the complexity of the scientific knowledge upon which to ..." |